Patricia F. Coogan

Patricia F. Coogan

Auto-generated profile, based on publicly available information

Patricia F. Coogan

Slone Epidemiology Center at Boston University Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
PCPatricia F. Coogan
Patricia F. Coogan
LWLaura F White
Laura F White
MJMichael Jerrett
Michael Jerrett
RBRobert D. Brook
Robert D. Brook
JSJason G. Su
Jason G. Su
LRLynn Rosenberg
Lynn Rosenberg
Background—: Evidence suggests that longer-term exposure to air pollutants over years confers higher risks of cardiovascular morbidity and mortality than shorter-term exposure. One explanation is that the cumulative adverse effects that develop over longer durations lead to the genesis of chronic disease. Preliminary epidemiological and clinical evidence suggests that air pollution may contribute to the development of hypertension and type 2 diabetes mellitus. Methods and Results—: We used Cox proportional hazards models to assess incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for incident hypertension and diabetes mellitus associated with exposure to fine particulate matter (PM 2.5 ) and nitrogen oxides in a cohort of black women living in Los Angeles. Pollutant levels were estimated at participants' residential addresses with land use regression models (nitrogen oxides) and interpolation from monitoring station measurements (PM 2.5 ). Over follow-up from 1995 to 2005, 531 incident cases of hypertension and 183 incident cases of diabetes mellitus occurred. When pollutants were analyzed separately, the IRR for hypertension for a 10-μg/m 3 increase in PM 2.5 was 1.48 (95% CI, 0.95–2.31), and the IRR for the interquartile range (12.4 parts per billion) of nitrogen oxides was 1.14 (95% CI, 1.03–1.25). The corresponding IRRs for diabetes mellitus were 1.63 (95% CI, 0.78–3.44) and 1.25 (95% CI, 1.07–1.46). When both pollutants were included in the same model, the IRRs for PM 2.5 were attenuated and the IRRs for nitrogen oxides were essentially unchanged for both outcomes. Conclusion—: Our results suggest that exposure to air pollutants, especially traffic-related pollutants, may increase the risk of type 2 diabetes mellitus and possibly of hypertension.

27 February 2014 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
YCYvette Cozier
Yvette Cozier
JYJeffrey Yu
Jeffrey Yu
PCPatricia F. Coogan
Patricia F. Coogan
TBTraci Bethea
Traci Bethea
LRLynn Rosenberg
Lynn Rosenberg
JPJulie R. Palmer
Julie R. Palmer
We assessed the relation of experiences of racism to the incidence of obesity and the modifying impact of residential racial segregation in the Black Women's Health Study, a follow-up study of US black women. Racism scores were created from 8 questions asked in 1997 and 2009 about the frequency of “everyday” racism (e.g., “people act as if you are dishonest”) and of “lifetime” racism (e.g., unfair treatment on the job). Residential segregation was measured by linking participant addresses to 2000 and 2010 US Census block group data on the percent of black residents. We used Cox proportional hazard models to estimate incidence rate ratios and 95% confidence intervals. Based on 4,315 incident cases of obesity identified from 1997 through 2009, both everyday racism and lifetime racism were positively associated with increased incidence. The incidence rate ratios for women who were in the highest category of everyday racism or lifetime racism in both 1997 and 2009, relative to those in the lowest category, were 1.69 (95% confidence interval: 1.45, 1.96; Ptrend < 0.01) and 1.38 (95% confidence interval: 1.15, 1.66; Ptrend < 0.01), respectively. These associations were not modified by residential segregation. These results suggest that racism contributes to the higher incidence of obesity among African American women.

1 March 2007 in Epidemiology
Verified
Journal Article
Closed access
PCPatricia F. Coogan
Patricia F. Coogan
LRLynn Rosenberg
Lynn Rosenberg
BSBrian L. Strom
Brian L. Strom
Statins affect the proliferation, survival, and migration of cancer cells, and it is thought that they may have chemopreventive properties in humans. The purpose of the present study was to evaluate the association between statin use and various types of cancer in our hospital-based case–control surveillance study. Data were collected from patients ages 40–79 years who were admitted to participating hospitals in 3 centers in Philadelphia, New York, and Baltimore from 1991 to 2005. Nurses administered questionnaires to obtain information on medication use and other factors. We compared patients who had any of 10 types of cancer (a total of 4913 patients) with controls admitted for noncancer diagnoses (3900 patients). The following cancers were examined individually: female breast (n = 1185), prostate (n = 1226), colorectal (n = 734), lung (n = 464), bladder (n = 240), leukemia (n = 254), pancreas (n = 220), kidney (n = 226), endometrial (n = 220), and non-Hodgkin lymphoma (n = 144). Logistic regression models were used to estimate odds ratios and 95% confidence intervals among regular statin users compared with never-users. Odds ratios were compatible with 1.0 for all cancer types. For the 4 largest cancer sites (breast, prostate, colorectum, and lung), odds ratios did not vary significantly by duration of statin use. Statins are among the most commonly used medications, and durations of use are increasing. The present data do not support either positive or negative associations between statin use and the occurrence of 10 cancer types. Cancer incidence should continue to be monitored among statin users.

1 April 2017 in Environmental Health Perspectives
Verified
Journal Article
Open access
MJMichael Jerrett
Michael Jerrett
MTMichelle C Turner
Michelle C Turner
BBBernardo S. Beckerman
Bernardo S. Beckerman
CPC. Arden Pope
C. Arden Pope
ADAaron van Donkelaar
Aaron van Donkelaar
RBRichard T. Burnett
Richard T. Burnett
Background: Remote sensing (RS) is increasingly used for exposure assessment in epidemiological and burden of disease studies, including those investigating whether chronic exposure to ambient fine particulate matter (PM2.5) is associated with mortality. Objectives: We compared relative risk estimates of mortality from diseases of the circulatory system for PM2.5 modeled from RS with that for PM2.5 modeled using ground-level information. Methods: We geocoded the baseline residence of 668,629 American Cancer Society Cancer Prevention Study II (CPS-II) cohort participants followed from 1982 to 2004 and assigned PM2.5 levels to all participants using seven different exposure models. Most of the exposure models were averaged for the years 2002–2004, and one RS estimate was for a longer, contemporaneous period. We used Cox proportional hazards regression to estimate relative risks (RRs) for the association of PM2.5 with circulatory mortality and ischemic heart disease. Results: Estimates of mortality risk differed among exposure models. The smallest relative risk was observed for the RS estimates that excluded ground-based monitors for circulatory deaths [RR = 1.02, 95% confidence interval (CI): 1.00, 1.04 per 10 μg/m3 increment in PM2.5]. The largest relative risk was observed for the land-use regression model that included traffic information (RR = 1.14, 95% CI: 1.11, 1.17 per 10 μg/m3 increment in PM2.5). Conclusions: We found significant associations between PM2.5 and mortality in every model; however, relative risks estimated from exposure models using ground-based information were generally larger than those estimated using RS alone. Citation: Jerrett M, Turner MC, Beckerman BS, Pope CA III, van Donkelaar A, Martin RV, Serre M, Crouse D, Gapstur SM, Krewski D, Diver WR, Coogan PF, Thurston GD, Burnett RT. 2017. Comparing the health effects of ambient particulate matter estimated using ground-based versus remote sensing exposure estimates. Environ Health Perspect 125:552–559; http://dx.doi.org/10.1289/EHP575

8 September 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DBDeborah A. Boggs
Deborah A. Boggs
LRLynn Rosenberg
Lynn Rosenberg
YCYvette Cozier
Yvette Cozier
Lauren WiseLauren Wise
Lauren Wise
PCPatricia F. Coogan
Patricia F. Coogan
JPJulie R. Palmer
Julie R. Palmer
Recent pooled analyses show an increased risk of death with increasing levels of the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 25.0 or higher in populations of European ancestry, a weaker association among East Asians, and no association of an increased BMI with an increased risk of death among South Asians. The limited data available on blacks indicate that the risk of death is increased only at very high levels of BMI (≥35.0). We prospectively assessed the relation of both BMI and waist circumference to the risk of death among 51,695 black women with no history of cancer or cardiovascular disease who were 21 to 69 years of age at study enrollment. Our analysis was based on follow-up data from 1995 through 2008 in the Black Women's Health Study. Multivariable proportional-hazards models were used to estimate hazard ratios and 95% confidence intervals. Of 1773 deaths identified during follow-up, 770 occurred among 33,916 women who had never smoked. Among nonsmokers, the risk of death was lowest for a BMI of 20.0 to 24.9. For a BMI above this range, the risk of death increased as the BMI increased. With a BMI of 22.5 to 24.9 as the reference category, multivariable-adjusted hazard ratios were 1.12 (95% confidence interval [CI], 0.87 to 1.44) for a BMI of 25.0 to 27.4, 1.31 (95% CI, 1.01 to 1.72) for a BMI of 27.5 to 29.9, 1.27 (95% CI, 0.99 to 1.64) for a BMI of 30.0 to 34.9, 1.51 (95% CI, 1.13 to 2.02) for a BMI of 35.0 to 39.9, and 2.19 (95% CI, 1.62 to 2.95) for a BMI of 40.0 to 49.9 (P<0.001 for trend). A large waist circumference was associated with an increased risk of death from any cause among women with a BMI of less than 30.0. The risk of death from any cause among black women increased with an increasing BMI of 25.0 or higher, which is similar to the pattern observed among whites. Waist circumference appeared to be associated with an increased risk of death only among nonobese women. (Funded by the National Cancer Institute.)

1 May 2002 in Epidemiology
Verified
Journal Article
Closed access
PCPatricia F. Coogan
Patricia F. Coogan
LRLynn Rosenberg
Lynn Rosenberg
JPJulie R. Palmer
Julie R. Palmer
BSBrian L. Strom
Brian L. Strom
AZAnn G. Zauber
Ann G. Zauber
SSSamuel Shapiro
Samuel Shapiro
Laboratory data suggest that the cholesterol-lowering “statin” drugs may have chemopreventive potential against cancer at various sites, including breast and prostate. However, in one trial of pravastatin there was a significant excess of breast cancer in the treatment group. In the present study, we assessed the relation of statin use to the risk of breast and prostate cancer in our hospital-based Case-Control Surveillance Study of Drugs and Serious Illnesses. Cases were 1,132 women with breast cancer and 1,009 men with prostate cancer; controls were 1,331 women and 1,387 men admitted for conditions unrelated to statin use. We used multivariate unconditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for use of statins compared with no use. The OR for breast cancer among statin users was 1.5 (95% CI = 1.0–2.3), largely accounted for by an OR of 1.8 (95% CI = 0.9–3.6) among cases with carcinoma in situ. Among invasive cases, the OR was 1.2 (95% CI = 0.7–2.0). The odds ratio for prostate cancer overall was 1.2 (95% CI = 0.8–1.7), and it was 1.4 (95% CI = 0.7–2.5) for Stage A. The data from the present study do not support a protective effect of statins against breast or prostate cancer. Detection bias is a possible explanation for the higher ORs observed for carcinoma in situ or early-stage cancer as compared with more invasive cancer.